Kringle Pharma (TSE:4884) Tax Provision: 円-1.77 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4884 Kringle Pharma Inc TSE:4884
45 GF Score
Price 円347.00
GF Value 円484.78
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Tax Provision?

Kringle Pharma TSE:4884 +1.76% 45 Tax Provision is 円-1.77 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 45/100 and a GF Value™ of 円484.78 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Kringle Pharma's tax provision for the three months ended in Mar. 2026 was 円-0.64 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was 円-1.77 Mil.

Kringle Pharma Tax Provision Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Tax Provision Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Tax Provision
Get a 7-Day Free Trial -1.49 -1.49 -1.49 -1.49 -1.50

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.37 -0.38 -0.37 -0.64
TSE:4884
45GF Score
Kringle Pharma Inc TSE:4884
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of 円-1.77 Mil mean?
Kringle Pharma (TSE:4884) has a Tax Provision of 円-1.77 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Tax Provision too high?
Kringle Pharma's current Tax Provision is 円-1.77 Mil. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Tax Provision compare to VRTX and REGN?
Kringle Pharma's Tax Provision of 円-1.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Tax Provision is 円-1.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Modestly Undervalued. The stock's GF Value™ is 円484.78, compared to a current price of 円347.00 — trading 28.4% below its estimated fair value. The current Tax Provision is 円-1.77 Mil. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Tax Provision is 円-1.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円347.00 is trading 28.4% below its estimated GF Value™ of 円484.78. GuruFocus considers Kringle Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4884:

  • Tax Provision: 円-1.77 Mil
  • GF Value™: 円484.78 vs. price of 円347.00 (28.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score

Get the complete analysis for TSE:4884

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円347.00
Price
円484.78
GF Value